<DOC>
	<DOCNO>NCT01502501</DOCNO>
	<brief_summary>The intent clinical study answer question : 1 . Is propose treatment safe 2 . Is treatment effective improve disease pathology patient Heart Disease assess series measurement indicate improvement , stability , degradation patient 's cardiovascular function exercise capacity ?</brief_summary>
	<brief_title>Safety Efficacy Adipose Derived Stem Cells Non-Ischemic Congestive Heart Failure</brief_title>
	<detailed_description>This open-label , non-randomized , multi-center patient-sponsored study design ass safety cardiovascular effect Adipose-derived Stem Cell ( ASC ) implantation use catheter delivery system patient nonischemic congestive heart failure . A percutaneous transluminal endomyocardial injection catheter use delivery ASCs . The therapy compose cell isolated patient 's adipose tissue . Liposuction perform collect adipose tissue specimen subsequent process isolate stem cell .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Willing able sign inform consent 2 . Age &gt; 18 year &lt; 80 year 3 . NYHA Class IIIV 4 . Congestive Heart Failure without acute coronary syndrome prior 6 month 5 . LVEF le equal 40 % measure echocardiography local investigative site , AND Left ventricular wall without mural thrombus thickness great 0.5 cm No significant valvular disease include : Moderatetosevere mitral regurgitation ( 34+ ) , aorticstenosis ( valve area &lt; 1.5 cm2 ) , aortic insufficiency ( 34+ ) 6 . Up date age gender appropriate cancer screen per American Cancer Society 1 . Limiting symptom due nonCHF cause , lung disease , peripheral vascular disease , arthritis musculoskeletal disorder 2 . Inability complete 6minute walk test reason 3 . Need intravenous CHF medication , chronic continuous oxygen therapy oral steroid , 4 . Coronary Artery Bypass Surgery ( CABG ) surgery within 60 day prior screen 5 . Planned revascularization within 4 month follow enrollment 6 . Aortic aneurysm dilatation ( &gt; 3.8 cm echocardiography image modality ) 7 . Peripheral vascular disease distal aorta may interfere catheter use 8 . Hemodynamically significant pericardial disease 9 . Prior aortic mitral valve replacement 10 . Biventricular pace device implant within last 3 month OR whose device schedule revise follow enrollment trial 11 . Scheduled receive history cardiac transplant , surgical remodeling procedure , leave ventricular assist device 12 . Stroke within 180 day screen 13 . Positive pregnancy test woman child bear potential unwilling use acceptable method contraception . 14 . Drug alcohol dependence 15 . Life expectancy less 1 year 16 . History cancer ( nonmelanoma skin cancer situ cervical cancer ) last five year 17 . Exposure angiogenic therapy ( include myocardial laser ) another investigational drug within 60 day screen , enrollment concurrent study may confound result study 18 . Any factor opinion Investigator render patient unsuitable participation , interfere conduct study interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CHF</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Non-Ischemic</keyword>
	<keyword>nonischemic</keyword>
	<keyword>nonischemia</keyword>
</DOC>